Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 14,196 Cr.
- Current Price ₹ 591
- High / Low ₹ 737 / 469
- Stock P/E 78.3
- Book Value ₹ 78.7
- Dividend Yield 0.34 %
- ROCE 16.8 %
- ROE 12.8 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 7.51 times its book value
- Earnings include an other income of Rs.90.4 Cr.
- Dividend payout has been low at 8.81% of profits over last 3 years
- Working capital days have increased from 173 days to 293 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap Nifty MidSmallcap 400
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
282 | 334 | 511 | 837 | 1,006 | 1,046 | 1,094 | |
230 | 249 | 361 | 668 | 828 | 878 | 913 | |
Operating Profit | 53 | 86 | 150 | 169 | 178 | 168 | 180 |
OPM % | 19% | 26% | 29% | 20% | 18% | 16% | 17% |
12 | -24 | 30 | 28 | 37 | 50 | 90 | |
Interest | 1 | 3 | 4 | 3 | 6 | 7 | 6 |
Depreciation | 4 | 13 | 18 | 24 | 32 | 31 | 26 |
Profit before tax | 59 | 46 | 159 | 170 | 177 | 181 | 238 |
Tax % | 14% | 30% | 17% | 22% | 26% | 24% | 24% |
51 | 32 | 132 | 133 | 130 | 138 | 181 | |
EPS in Rs | 324.22 | 202.30 | 843.58 | 755.26 | 5.87 | 6.20 | 7.55 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 26% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 9% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | 11% |
TTM: | 46% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 11% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 14% |
Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.31 | 0.30 | 0.30 | 0.40 | 44 | 44 | 48 |
Reserves | 158 | -3 | 254 | 650 | 751 | 909 | 1,840 |
106 | 362 | 23 | 44 | 51 | 38 | 27 | |
57 | 72 | 96 | 156 | 191 | 228 | 234 | |
Total Liabilities | 322 | 431 | 373 | 850 | 1,038 | 1,220 | 2,150 |
8 | 31 | 41 | 72 | 78 | 56 | 53 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Investments | 134 | 251 | 83 | 203 | 400 | 624 | 975 |
180 | 148 | 249 | 575 | 559 | 540 | 1,119 | |
Total Assets | 322 | 431 | 373 | 850 | 1,038 | 1,220 | 2,150 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
62 | 90 | 53 | 38 | 82 | 176 | 129 | |
-70 | -51 | -34 | -267 | -51 | -189 | -825 | |
15 | -18 | -37 | 245 | -17 | -16 | 717 | |
Net Cash Flow | 8 | 20 | -18 | 16 | 14 | -29 | 22 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 65 | 65 | 125 | 152 | 145 | 132 | 137 |
Inventory Days | |||||||
Days Payable | |||||||
Cash Conversion Cycle | 65 | 65 | 125 | 152 | 145 | 132 | 137 |
Working Capital Days | 51 | 21 | 84 | 107 | 118 | 109 | 293 |
ROCE % | 28% | 49% | 36% | 24% | 18% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Directorate
1d - AGM on June 26, 2025; final dividend ₹2/share; re-appointment of independent director Dr. Papathomas.
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 1d
-
Record Date For The Purpose Of Dividend
1d - AGM set for June 26, 2025; final dividend ₹2/share; re-appointment of independent director approved.
-
Intimation Of Outcome Of Board Meeting
1d - AGM on June 26, ₹2 final dividend, and re-appointment of independent director Dr. Papathomas.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Schedule of investor meetings on May 29-30, 2025, with no price sensitive info shared.
Concalls
-
May 2025Transcript PPT REC
-
Mar 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.